Related Experiment Video
Updated: Sep 17, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
RNA-ssisting immunity to heal the heart: a new frontier in therapeutics
Joel Gregory Rurik1, Christian Le Phu2, Julian Mustroph2
1Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm 17177, Sweden.
Abstract:
Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful avenue for discovering novel therapeutics: leveraging ribonucleic acid (RNA) to tip the immunological balance toward tissue repair. Decades of research have primed the three disciplines of cardiology, immunology, and RNA drug development, to bring potent intersectional therapies to the clinic. We discuss both coding and non-coding RNA interventions across multiple cell types, such as monocytes, macrophages, and T cells, throughout different cardiovascular diseases. Altogether, advanced RNA-based medicines targeting the immune system are primed to transform how cardiovascular diseases are treated.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Heart Failure Drugs: Inotropic Agents
Myocarditis IV: Nursing Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiomyopathy IV: Restrictive Cardiomyopathy

